Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332072 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension
A Phase 3 study of Ocular Hypertension, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 541
- Enrollment target
- 1
- Study location
NCT00332072 is a Phase 3 study of Ocular Hypertension that has completed, run by Allergan. The registered enrollment target is 541 participants, above the 268-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (102% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00332072, a Phase 3 study of Ocular Hypertension, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 541 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety and efficacy of Bimatoprost/Timolol Fixed Combination in the treatment of glaucoma or ocular hypertension
Conditions Studied
Interventions
- DRUG bimatoprost/timolol fixed combination
Study Locations (1)
Utah
- - Ogden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 541 participants |
| Start Date | 2001-08 |
| Est. Completion | 2003-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00332072
The ClinicalTrials.gov registry entry for NCT00332072 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 541 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 268-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (102% higher). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ocular Hypertension appearing as the primary indexed condition, and to 1 intervention - of which bimatoprost/timolol fixed combination is the first listed.
NCT00332072 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT00332072 about?
NCT00332072 is a clinical study titled "Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension". The purpose of this study is to assess the safety and efficacy of Bimatoprost/Timolol Fixed Combination in the treatment of glaucoma or ocular hypertension
What is the current status of trial NCT00332072?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 541 participants. The study started on 2001-08. Estimated completion is 2003-08.
What conditions does trial NCT00332072 study?
This clinical trial studies the following conditions: Ocular Hypertension.
What interventions are being tested in trial NCT00332072?
The interventions under investigation include: bimatoprost/timolol fixed combination (DRUG).
Who is sponsoring clinical trial NCT00332072?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00332072 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.